AstraZeneca Stock And 2 AI Healthcare Names Worth A Closer Look

US 10 year Treasury yields remain elevated as investors fund large capital spending plans tied to AI infrastructure. Higher funding costs are pushing many healthcare groups to lean harder on AI to raise productivity and cut waste. That creates a wider opening for Transformative AI Healthcare Stocks that aim to help hospitals and drug developers do more with each dollar. This article highlights three stand out stocks from that screener.

The three stocks that follow are just a starting sample from this theme. The full screen surfaced 3 more companies with equally compelling narratives that are not covered in the article below. To identify and analyze your own highest conviction ideas in this space, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Overview: Haleon is a global consumer healthcare company behind OTC brands like Sensodyne, Panadol, Advil and Centrum, and is working with Microsoft to apply AI, data and digital tools to product development, personalized consumer health solutions and its commercial and supply chain operations. That means most revenue still comes from familiar pharmacy products, while the AI partnership is a targeted effort to make the business faster, more productive and more tailored to individual consumer needs.

Operations: Haleon generates about £3.8b of revenue in North America, £4.7b in Europe, the Middle East, Africa and Latin America, and £2.6b in Asia Pacific.

Market Cap: £31.3b

Haleon gives you exposure to everyday consumer health brands plus an AI angle through its broad collaboration with Microsoft, which is aimed at using Azure and Copilot to support scientific work, marketing and supply chain efficiency. The company also faces a high debt load, rising regulatory and compliance costs and questions over how quickly it can refresh its product pipeline as consumer tastes move toward more natural remedies. The impact of the AI initiatives and developments in markets such as India may influence how investors view the current valuation and the prevailing narrative around the stock.

Haleon’s AI partnership with Microsoft could be reshaping everyday consumer health behind the scenes, while its debt load and regulatory pressures still hang over the story. Get the fuller picture with the 4 key rewards and 1 important warning sign

Build your own AI healthcare shortlist

Haleon and the other two stocks in this list are examples of what can surface when you use a focused screener. Use our customisable Screener to combine filters on valuation, growth, balance sheet strength and risks into a shortlist that fits your style, or jump straight into our curated Investing Ideas.

IXICO (AIM:IXI)

Overview: IXICO is a London based medical data analytics company that runs AI enabled neuroimaging and clinical data services for drug developers, using its IXICO platform to manage and analyse brain scans and other trial data in conditions such as Alzheimer’s, Huntington’s, multiple sclerosis and Parkinson’s disease.

Operations: IXICO generates about £7.3 million of revenue from Medical Labs & Research services, centered on neuroimaging and trial analytics.

Market Cap: £16.4 million

IXICO gives you targeted exposure to AI in healthcare through its neuroimaging platform, which supports drug trials with AI driven radiological reads and biomarker analytics in complex brain diseases. Recent contracts in Alzheimer’s imaging, a planned revenue outcome of at least £8 million for FY 2026 and a new collaboration with the Paris Brain Institute indicate that clients are engaging with this specialist capability. The trade off is clear: the company is still loss making, relies on higher risk funding sources and has diluted shareholders while it builds scale. For investors who can tolerate a small cap with execution risk, the combination of focused AI healthcare exposure and a modest valuation on sales may merit closer consideration.

IXICO’s AI neuroimaging work in Alzheimer’s and other brain diseases is gaining traction while the stock still prices in small cap risk. Before you write it off as too early, read the 2 key rewards and 3 important warning signs (2 are major!)

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company that develops and sells prescription medicines across oncology, cardiovascular and metabolic disease, respiratory and immunology, vaccines and rare diseases. The company is also working with Tempus, Pathos and Nucs AI on large scale oncology AI models and response prediction tools aimed at sharpening cancer diagnosis, treatment selection and drug research.

Operations: AstraZeneca generates about $61.4b of revenue from pharmaceuticals.

Market Cap: £183.1b

Investors looking at AstraZeneca are really looking at two stories in one. The first is a large oncology and chronic disease portfolio supported by a late stage pipeline and margins around 17%. The second is a set of focused AI collaborations in cancer, where work with Tempus, Pathos, Nucs AI and others aims to turn massive imaging and genomic datasets into diagnostics and treatment predictions. The company also faces high debt, ongoing price pressure on blockbuster drugs and the cost of heavy R&D, so execution risk is present. The potential appeal is that if the oncology pipeline and AI enabled tools deliver, AstraZeneca could combine scale with more precise medicine and leaner development, which current valuations may or may not fully reflect.

AstraZeneca’s oncology engine and cancer focused AI work could be masking where the real inflection sits for this stock. Before you assume the market has priced it all in, read the 4 key rewards and 2 important warning signs

Seeking Alternatives Before The Crowd?

Fresh stock ideas can move from quiet to breakout territory quickly. Screens fill up once momentum is obvious. Check under the radar themes while it matters and get in early.

• Target resilient cash generators before defensive demand sends yields higher by reviewing the 7 dividend fortresses while these higher income opportunities are still under the radar for now.
• Track early movers in automation and factory efficiency by scanning the curated 37 robotics and automation stocks before institutional money sends the best operators out of your price range.
• Position ahead of potential infrastructure momentum by checking the focused 39 power grid technology and infrastructure stocks while upgrades, capacity builds and grid technology contracts are still thinly covered.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com